Less weight gain and hypoglycaemia with once-daily insulin detemir than with NPH insulin in basal-bolus therapy of overweight type 2 diabetes patients: The PREDICTIVE-BMT trial

被引：0
|
作者：
Montanana, C. Fajardo
Herrero, C. Hernandez
Fernandez, M. Rivas
机构：
[1] Hosp Virgen Macarena, Seville, Spain
[2] Hosp Infantil Luisa, Seville, Spain
来源：
DIABETOLOGIA | 2007年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0978
引用
收藏
页码：S404 / S404
页数：1
相关论文
共 50 条
  • [21] Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE™ study
    Yenigun, M.
    Honka, M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (03) : 425 - 432
  • [22] Compared to NPH insulin, insulin detemir is associated with a superior efficacy: tolerability profile and reduced excess weight gain when used in basal-bolus therapy for children and adolescents with type 1 diabetes
    Robertson, Kenneth
    Gall, Mari Anne
    HORMONE RESEARCH, 2006, 65 : 57 - 57
  • [23] Insulin glargine is associated with less hypoglycaemia than NPH insulin in older patients with Type 2 diabetes
    Riddle, M
    Massi-Benedetti, M
    Häring, HU
    Dailey, G
    Murray, F
    Lin, Z
    Rosenstock, J
    DIABETOLOGIA, 2004, 47 : A328 - A328
  • [24] Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes
    Hermansen, K
    Derezinski, T
    Kim, H
    Gall, MA
    DIABETOLOGIA, 2004, 47 : A273 - A274
  • [25] Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
    Tosaka, Yuka
    Kanazawa, Akio
    Ikeda, Fuki
    Iida, Mayu
    Sato, Junko
    Matsumoto, Kazuhisa
    Uchida, Toyoyoshi
    Tamura, Yoshifumi
    Ogihara, Takeshi
    Mita, Tomoya
    Shimizu, Tomoaki
    Goto, Hiromasa
    Ohmura, Chie
    Fujitani, Yoshio
    Watada, Hirotaka
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [26] Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart
    Vague, P
    Selam, JL
    Skeie, S
    De Leeuw, I
    Elte, JWF
    Haahr, H
    Kristensen, A
    Draeger, E
    DIABETES CARE, 2003, 26 (03) : 590 - 596
  • [27] Study of Once-Daily Levemir (SOLVE™): Weight Changes Associated With the Initiation of Once-Daily Insulin Detemir in Chinese Patients With Type 2 Diabetes
    Pan, Changyu
    Ji, Qiuhe
    Li, Yanbing
    DIABETES, 2012, 61 : A612 - A612
  • [28] Once-daily dosing of insulin detemir is associated with lower risk of hypoglycaemia at similar levels of HbA1c compared to once-daily NPH insulin in subjects with type 1 diabetes mellitus
    Shaw, J. E.
    Larsen, J.
    Pedersen, C. B.
    Tang-Fui, S.
    DIABETOLOGIA, 2008, 51 : S391 - S391
  • [29] Effect of Once-Daily Detemir vs NPH Insulin on Body Weight and Metabolic Control When Added to OADs in Type 2 Diabetes
    Catrinoiu, Doina
    Veresiu, Ioan Andrei
    Botnariu, Eosefina Gina
    DIABETES, 2009, 58 : A521 - A521
  • [30] Transferring to insulin detemir basal-bolus therapy improves glycaemic control and reduces hypoglycaemia without weight gain in Type 2 diabetes: comparison of 26-week data from two PREDICTIVE™ studies
    Dornhorst, A.
    Merilainen, M.
    Koenen, C.
    Looij, B-J
    DIABETIC MEDICINE, 2008, 25
12345